Table 3 Regression estimates used to estimate the Incremental Net Benefit

Cost, ΔC (in 2020 €)

N/R

1096

–

Effect, ΔE1 (QALY)

\(E_{1A} = \alpha_{0} + \alpha_{1} Ladnaan + \alpha_{2} BaseEQ5D\)

0.003

0.000–0.004

\(E_{1B} = \alpha_{0} + \alpha_{1} Ladnaan + \alpha_{2} BaseEQ5D + \alpha_{3} Confounders\)

0.002

0.000–0.004

Effect, ΔE2 (CBCL)

\(E_{2A} = \gamma_{0} + \gamma_{1} Ladnaan + \gamma_{2} BaseCBCL\)

− 2.56

− 3.69 to − 1.43

\(E_{2B} = \gamma_{0} + \gamma_{1} Ladnaan + \gamma_{2} BaseCBCL + \gamma_{3} Confounders\)

− 2.34

− 3.47 to − 1.22

0

578,923

\(\begin{gathered} {\text{NB}} = \theta_{0} + \theta_{1} Ladnaan + \theta_{2} Basecost + \theta_{3} BaseCBCL \hfill \\ + \theta_{4} BaseEQ5D + \theta_{5} Confounders + \varepsilon_{nb - p} \hfill \\ \end{gathered}\)

0

− 1153.56 to 1161.40

100

386,816

–

0

− 872.18 to 889.71

200

194,710

–

0

− 680.72 to 650.98

302

0

–

2.34

− 667.78 to 672.47